12.13 USD
+0.03 (+0.25%)
12.13 USD
0 (0%)
OCUL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. The financial health of OCUL is average, but there are quite some concerns on its profitability. OCUL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
OCUL had negative earnings in the past year.
OCUL had a negative operating cash flow in the past year.
In the past 5 years OCUL always reported negative net income.
OCUL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
OCUL's Return On Assets of -60.77% is on the low side compared to the rest of the industry. OCUL is outperformed by 64.06% of its industry peers.
OCUL has a worse Return On Equity (-96.69%) than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.77% | ||
| ROE | -96.69% | ||
| ROIC | N/A |
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of OCUL (88.87%) is better than 91.15% of its industry peers.
In the last couple of years the Gross Margin of OCUL has grown nicely.
The Profit Margin and Operating Margin are not available for OCUL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
2. Health
2.1 Basic Checks
OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCUL has more shares outstanding
Compared to 5 years ago, OCUL has more shares outstanding
The debt/assets ratio for OCUL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.41 indicates that OCUL is not in any danger for bankruptcy at the moment.
The Altman-Z score of OCUL (5.41) is better than 77.08% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that OCUL is not too dependend on debt financing.
OCUL's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. OCUL outperforms 43.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.41 |
ROIC/WACCN/A
WACC9.38%
2.3 Liquidity
OCUL has a Current Ratio of 7.85. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.85, OCUL is doing good in the industry, outperforming 74.48% of the companies in the same industry.
OCUL has a Quick Ratio of 7.78. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.78, OCUL is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.78 |
3. Growth
3.1 Past
OCUL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.88%.
Looking at the last year, OCUL shows a decrease in Revenue. The Revenue has decreased by -9.21% in the last year.
OCUL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 72.02% yearly.
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
3.2 Future
Based on estimates for the next years, OCUL will show a very strong growth in Earnings Per Share. The EPS will grow by 20.11% on average per year.
OCUL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 50.68% yearly.
EPS Next Y-1.48%
EPS Next 2Y1.94%
EPS Next 3Y6%
EPS Next 5Y20.11%
Revenue Next Year-13.73%
Revenue Next 2Y0.79%
Revenue Next 3Y15.87%
Revenue Next 5Y50.68%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
OCUL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OCUL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.94%
EPS Next 3Y6%
5. Dividend
5.1 Amount
No dividends for OCUL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.13
+0.03 (+0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners90.09%
Inst Owner Change19.84%
Ins Owners2.76%
Ins Owner Change-0.22%
Market Cap2.56B
Revenue(TTM)55.78M
Net Income(TTM)-249.67M
Analysts86.32
Price Target22.78 (87.8%)
Short Float %6.77%
Short Ratio4.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.72%
Min EPS beat(2)-7.83%
Max EPS beat(2)-1.62%
EPS beat(4)0
Avg EPS beat(4)-12.26%
Min EPS beat(4)-26.63%
Max EPS beat(4)-1.62%
EPS beat(8)1
Avg EPS beat(8)-40.57%
EPS beat(12)4
Avg EPS beat(12)-25.42%
EPS beat(16)6
Avg EPS beat(16)-13.78%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)-0.44%
Revenue beat(4)0
Avg Revenue beat(4)-10.82%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)-0.44%
Revenue beat(8)1
Avg Revenue beat(8)-8.36%
Revenue beat(12)3
Avg Revenue beat(12)-6.11%
Revenue beat(16)3
Avg Revenue beat(16)-8.25%
PT rev (1m)25.23%
PT rev (3m)27.29%
EPS NQ rev (1m)6.16%
EPS NQ rev (3m)15.57%
EPS NY rev (1m)0%
EPS NY rev (3m)4.34%
Revenue NQ rev (1m)-2.4%
Revenue NQ rev (3m)-1.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 45.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 9.9 | ||
| P/tB | 9.9 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.26
BVpS1.22
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.77% | ||
| ROE | -96.69% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.87% | ||
| FCFM | N/A |
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
F-Score2
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 232.75% | ||
| Cap/Sales | 16.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.85 | ||
| Quick Ratio | 7.78 | ||
| Altman-Z | 5.41 |
F-Score2
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)138.13%
Cap/Depr(5y)98.78%
Cap/Sales(3y)6.55%
Cap/Sales(5y)5.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y-1.48%
EPS Next 2Y1.94%
EPS Next 3Y6%
EPS Next 5Y20.11%
Revenue 1Y (TTM)-9.21%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-5.71%
Revenue Next Year-13.73%
Revenue Next 2Y0.79%
Revenue Next 3Y15.87%
Revenue Next 5Y50.68%
EBIT growth 1Y-77.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-59.92%
EBIT Next 3Y-8.65%
EBIT Next 5Y23.93%
FCF growth 1Y-175.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-193.62%
OCF growth 3YN/A
OCF growth 5YN/A
OCULAR THERAPEUTIX INC / OCUL FAQ
What is the ChartMill fundamental rating of OCULAR THERAPEUTIX INC (OCUL) stock?
ChartMill assigns a fundamental rating of 3 / 10 to OCUL.
What is the valuation status for OCUL stock?
ChartMill assigns a valuation rating of 0 / 10 to OCULAR THERAPEUTIX INC (OCUL). This can be considered as Overvalued.
How profitable is OCULAR THERAPEUTIX INC (OCUL) stock?
OCULAR THERAPEUTIX INC (OCUL) has a profitability rating of 1 / 10.
What is the expected EPS growth for OCULAR THERAPEUTIX INC (OCUL) stock?
The Earnings per Share (EPS) of OCULAR THERAPEUTIX INC (OCUL) is expected to decline by -1.48% in the next year.